EXPERIMENTAL IMMUNOTHERAPY OF MICE WITH TRANSPLANTED MC-RHABDOMYOSARCOMA RESISTANT TO DOXORUBICIN
Ninel M. Berezhnaya*, Elena V. Kovalchuk, Yulya D. Vinnichuk, Svetlana I. Spivak, Oxana B. Belova
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine
Abstract. Aim: To compare the sensitivity of doxorubicin (DOX) sensitive and DOX-resistant MC-rhabdomyosarcoma (MC-RMS) cells to the action of lymphokine-activated cells (LAC). Results:In vitro investigations showed that LAC received from the fraction of adherent lymphocytes possess the highest activity against DOX-resistant tumor cells, and LAC from lymphocytes of total pool — against DOX-resistant tumor cells pretreated with DOX at a low dose. Adoptive immunotherapy of MC-RMS in vivo showed the highest efficacy in the cases of LAC intratumoral injection and the one combined with intraperitoneal administration of DOX at a low dose (increase of survival time by 14% and 25%, respectively). Conclusion: Adoptive in vivo therapy of DOX-resistant Mh-RMS is effective if LAC or their combination with DOX at a low dose are administered.
